Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human, Mouse

Cited:

Human

Predicted:

Monkey (100%). Backed by our 100% Guarantee.

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Simple Western, Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

1.0 mg/ml

View all EGFR Antibodies »

Product Specifications

Immunogen

A synthetic peptide which maps to a region between residues 1150 and the C-terminus (residue 1210) of human Epidermal Growth Factor Receptor using the numbering given in Swiss-Prot entry P00533 (GeneID 1956).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Description

This antibody can be used as the primary antibody in a PLA assay with the following as complementing antibodies:NB200-171

Scientific Data Images for EGFR Antibody

Western Blot: EGFR Antibody [NB100-596]

Western Blot: EGFR Antibody [NB100-596]

Western Blot: EGFR Antibody [NB100-596] - NPM1 knockdown decreases EGF expression. NPM1 controls activation of the EGF/EGFR pathway downstream effectors. Proteins, extracted from shScr and shNPM1 LNCaP cells cultured in RPMI 1640 10%FBS, were electrophoresed by SDS-PAGE. Transferred membranes were immunoblotted with indicated antibodies. Histograms show the band quantification reported to the beta-actin level. Blots are representative of three independent experiments with consistent results. Data are representative of at least three independent experiments and are expressed as the mean +/- SD. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0096293), licensed under a CC-BY license.
Immunohistochemistry-Paraffin: EGFR Antibody [NB100-596]

Immunohistochemistry-Paraffin: EGFR Antibody [NB100-596]

Immunohistochemistry-Paraffin: EGFR Antibody [NB100-596] - Section of human placenta. Antibody: Affinity purified rabbit anti-EGFR used at a dilution of 1:1,000 (1ug/ml). Detection: DAB.
Western Blot: EGFR Antibody [NB100-596]

Western Blot: EGFR Antibody [NB100-596]

Western Blot: EGFR Antibody [NB100-596] - EGF R/ErbB1 Antibody [NB100-596] - Whole cell lysate (50 ug) from 293T and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody:Affinity purified rabbit anti-EGFR antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.
View 3 more images

Applications for EGFR Antibody

Application
Recommended Usage

Immunohistochemistry

1:500 - 1:2000

Immunohistochemistry-Paraffin

1:500 - 1:2000

Immunoprecipitation

2 - 10 ug/mg lysate

Western Blot

1:10000 - 1:25000
Application Notes
Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. See Simple Western Antibody Database for Simple Western validation: Tested in HeLa cell line; separated by size; antibody dilution of 1:100.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Preservative

0.09% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: EGFR

Epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, is a type I glycoprotein that belongs the ErbB subfamily of receptor tyrosine kinases (RTKs), which includes ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4 (1,2). EGFR plays an important role in epithelial cell development and homeostasis and as a driver of tumorigenesis in cancer (1,2). The human EGFR is protein 1210 amino acids (aa) in length with a theoretical molecular weight (MW) of 134 kDa (1). The protein consists of a short signal peptide, an extracellular domain (ECD) divided into four subdomains (I-IV), a transmembrane region, an intracellular juxtamembrane segment, a tyrosine kinase domain, and C-terminal tail (1-3). Within the ECD, human EGFR has 88-90% aa sequence identity with mouse and rat EGFR. EGFR has four known specific ligands: EGF, amphiregulin, epigen, and transforming growth factor alpha (TGF-alpha). EGFR ligands betacellulin, epiregulin, and herapin binding (HB)-EGF have dual specificity with ErbB4 (1,3). Ligand binding to the extracellular domain of EFGR leads to receptor homodimerization, or heterodimerization with other ErbB family members, and EGFR activation. This results in subsequent phosphorylation and activation of intracellular signaling pathways, such as MAPK and PI3K/Akt (2,3). EGFR signaling is essential for many cellular processes including proliferation, differentiation, migration, and apoptosis (1,3,5).

In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).

References

1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014

2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155

3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018

4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1

5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015

6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

Long Name

Epidermal Growth Factor Receptor

Alternate Names

EGF R, ErbB, ErbB1, HER-1

Entrez Gene IDs

1956 (Human); 13649 (Mouse)

Gene Symbol

EGFR

UniProt

P00533

Additional EGFR Products

Product Documents for EGFR Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for EGFR Antibody

This antibody can be used as the primary antibody in a PLA assay with the following as complementing antibodies:NB200-171

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.